Based on these results, we have demonstrated that co-administration of BCR::ABL1 inhibitors with recently developed FLT3 inhibitors, such as midostaurin or quizartinib, suppressed FLT3-TAZ signaling pathway, restored TKI sensitivity, and promoted cell death in FLT3+ BP-CML cells both in vitro and in vivo. Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.